Navigation Links
Women with AIDS face cervical cancer threat
Date:11/30/2007

Lusaka, ZambiaAccording to a report issued last week by UNAIDS, access to antiretroviral therapy is beginning to reduce AIDS mortality worldwide. But Dr. Groesbeck Parham, gynecologic oncologist and Director of the Cervical Cancer Prevention Program at the Center for Infectious Disease Research in Zambia (CIDRZ) warns that women being treated for AIDS could end up dying of cervical cancer unless they have access to screening and treatment.

We are saving womens lives by treating them with antiretroviral therapy, but we could lose a high percentage of them to cervical cancer, said Parham.

Parham and his team have tested more than 10,000 Zambian women in the largest cervical cancer screening program targeting HIV-infected women in the developing world. In a study published last year in the journal Gynecologic Oncology, he reported that 90 percent of HIV-infected women presenting for antiretroviral therapy also harbor cervical cell abnormalities, conditions that left untreated can develop into cervical cancer.

Before having access to antiretroviral medications, women living in developing nations who had AIDS typically succumbed to it before they could develop cervical cancer, said Parham.

Currently, 80 percent of new cases of cervical cancer and 80 percent of the annual deaths occur in women who live in developing countries. Few women in poor countries have access to cervical cancer screening or treatment.

As funds are allocated for HIV/AIDS care and treatment, we need to make sure that womens other health issues are not swept under the carpet, said Dr. Mulindi Mwanahamuntu, Co-Director of the CIDRZ Cervical Cancer Prevention Program.

In sub-Saharan Africa, cervical cancer is the most common female cancer and the most common cause of cancer-related death. When cervical lesions are discovered in pre-cancer stage the cure rates are high.

In the CIDRZ program, women are examined by nurses trained in a low-tech, low-cost screening pro
'/>"/>

Contact: Dale Hanson Bourke
Dale.Bourke@CIDRZ.org
301-652-6515
CIDRZ Foundation
Source:Eurekalert

2

GOOD

Page: 1 2

Related biology news :

1. Drug could improve pregnancy outcomes in wider range of women with insulin resistance
2. Women more depressed and men more impulsive with reduced serotonin functioning
3. Pregnant women at risk for unnecessary operations due to misdiagnosis of appendicitis
4. Cell response to stress signals predicts tumors in women with common pre-breast cancer
5. Too few women scientists achieving academic leadership positions
6. Gender roles and not gender bias hold back women scientists
7. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
8. A study by the MUHC and McGill University opens a new door to understanding cancer
9. ESF EURYI award winner aims to stop cancer cells reading their own DNA
10. Protein chatter linked to cancer activation
11. Newly created cancer stem cells could aid breast cancer research

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...utes fish food is a matter of debate. A high-profi...lmost 50 percent of their carbon from trees and le...errestrial and aquatic ecosystems. , But new res... is not likely to be true. Algae provide a much ri...ng to research published this week in the Proceed...
(Date:11/24/2009)... is available in Spanish . , The presence o...of inflammatory substances in the blood, hinders t...y a research project of the University of Navarra ... at the School of Pharmacy. , The project, entit...tion to the control of body weight and inflammatio...
(Date:11/23/2009)....C. The community-associated strain of the deadly...ant to most common antibioticsposes a far greater ...its way into hospitals, according to a study in th.... , The new threat is easily picked up in fitne...as increased the overall burden of MRSA within hos...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3It can be predicted the reaction obese patients will have to a diet 2New study finds MRSA on the rise in hospital outpatients 2Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 1Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 2Cancer Patients Benefit From Speed Accuracy of RapidArc Radiotherapy Treatments 51882 3Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments 51880 1Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments 51880 2Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments 51880 3Supelco 28R 29 and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water 13058 1Supelco 28R 29 and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water 13058 2Supelco 28R 29 and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water 13058 3
...bruary 22, 2009--Researchers at the Dana-Farber Ca...r Medical Research (Burnham) and the Centers for D...the identification of human monoclonal antibodies ...fluenza A viruses, including avian influenza A (H5...d some seasonal influenza viruses. These antibodie...
...L, N.J., Feb. 18 BIO-key International, Inc. (OTC...lease fourth quarter 2008 financial results on Tue...In conjunction with the release, BIO-key has sched...ve over the Internet on Tuesday, February 24, 2009... BIO-key International, Inc. Fourth Quarter 2...
...e quick decline of a tiny shrimp-like species, kno... aggressive population growth of non-native quagga...As invasive mussel numbers increase, food sources ...ily and unilaterally declined. , A recent researc...ratory published,this week in Freshwater Biology ...
Other Biology News:Scientists identify human monoclonal antibodies effective against bird and seasonal flu viruses 2Scientists identify human monoclonal antibodies effective against bird and seasonal flu viruses 3BIO-key(R) Announces Fourth Quarter and 2008 Year-End Earnings Release and Conference Call Schedule 2
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24 /PR...aq: DCGN ) today announced the approval of all of ...rt for the District of Delaware,(the "Bankruptcy C...n for,relief under Chapter 11 of the United States... The orders issued by the Bankruptcy Court all...
(Date:11/24/2009)..., SAN MATEO, Calif., Nov. 24 /PRNewswire-FirstCall...ceutical company focused on developing and commerc...d today that Anthony DiTonno, President and Chief ...21st Annual Piper Jaffray Health Care Conference, ...ce Hotel in New York, New York. ,, Mr. DiTonno...
(Date:11/24/2009)...ATTLE, Nov. 24 Blue Marble Energy ...ssa Public Development Authority (OPDA) were recen...nity Economic Revitalization Board (CERB) in a pri...irst specialty biochemical biorefinery in Lincoln ...antly speed the development of our biorefinery and...
(Date:11/24/2009)... Primary efficacy endpoint has been met for pat...rial cancer, , QUEBEC CITY, Nov. 24 /PRNewswi...ZS ; TSX: AEZ) (the "Company"), a global biopharma...oncology, today announced positive efficacy data f...ptide conjugate, AEZS-108 (formerly AN-152), in pa...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
.../Xinhua-PRNewswire-FirstCall/ --,China Biologic Pr... "the,Company"), one of the leading plasma-based p...f China ("PRC"), today announced that the Company,...Drug Administration,("SFDA") (1) to start the prod...od product prepared from plasma and (2) to commenc...
...PRNewswire/ -- Today, Tigermed,Consulting Ltd. joi...in,their CRO Service Alliance CROSA that provides ...nies. Tigermed,s expertise in clinical,development...aceutical,development capabilities of the alliance...Sciences entered into a,CRO Service Alliance in Ma...
...FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ...cused on,endocrine therapy and oncology, today ann..., Chairman and CEO of Andros Men,s Health Institut...er Presentation in a Poster,Session at the 23rd An...h,was held March 26-28, 2008 in Milan, Italy. Titl...
Other Biology Technology:China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex 2China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex 3Shanghai CRO Service Alliance Adds Clinical Development Capabilities 2Shanghai CRO Service Alliance Adds Clinical Development Capabilities 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 2AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 3AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 4AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 5AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan 6
...stone and M.W. Turner (1997). • This book des...production of high-quality antibodies, the use of ... antibodies and antigens, the latest ELISA techniq...assays for detecting cell-surface molecules (cell-...
Propidium Iodide (1 mg/ml). from BioVision
Vybrant Apoptosis Assay Kit #7 - Hoechst 33342/YO-PRO-1/propidium iodide - 200 assays from Molecular Probes (Invitrogen)
Rat TIMP-1 ELISA Kit from R&D Systems
Biology Products: